Maximizing Asset Value in Rare Kidney Disease: Expanding from IgA to New Indications & Designing Proof-of-Concept Trials to Accelerate Development

• Leveraging clinical success in one indication to de-risk expansion into new rare kidney diseases
• Designing efficient proof-of-concept trials in small, heterogeneous patient populations
• Aligning indication expansion strategies with regulatory expectations and endpoint selection
• Balancing speed, cost, and probability of success when advancing pipeline-in-aproduct strategies

Speakers:

Joshua Waitzman

Senior Medical Director

Vera Therapeutics